Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Evaxion Biotech A/S (NASDAQ: EVAX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.